Hidenori Matsuo

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 925 citations

Life Sciences, Neurology, Neuroscience +11

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Ankle-Brachial Blood Pressure Index Predicts All-Cause and Cardiovascular Mortality in Hemodialysis Patients

Kumeo Ono, Akiyasu Tsuchida, Hironobu Kawai et al. · Journal of the American Society of Nephrology · 2003 · 227 citations

Medicine, Internal Medicine, Nephrology +15

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Surgery +5

Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE)

Tomohiko Kayashima, Hidenori Matsuo, Akira Satoh et al. · Journal of Human Genetics · 2002 · 116 citations

Medicine, Genetics, Molecular Genetics +8